Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + sunitinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A two-drug oral combination of the mTOR inhibitor everolimus and the multi‑target VEGF/PDGF receptor tyrosine kinase inhibitor sunitinib, investigated primarily in metastatic renal cell carcinoma to achieve simultaneous inhibition of the PI3K/AKT/mTOR pathway and angiogenic signaling. Phase I studies found the combination produced responses but was associated with significant acute and chronic toxicities, and was only tolerated at attenuated doses or modified schedules; daily coadministration was poorly tolerated, and weekly everolimus with reduced‑dose sunitinib was the most feasible regimen explored.[3][2][1]
- Other names
- everolimus and sunitinibsunitinib plus everolimus
02
Targets
FKBP1APDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)Mechanistic target of rapamycin complex 1VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on everolimus + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + sunitinib.